NCT05223231View on ClinicalTrials.gov

Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

486

Participants

Timeline

Start Date

February 24, 2022

Primary Completion Date

October 22, 2025

Study Completion Date

October 22, 2025

Conditions
Advanced Malignant Tumors
Interventions
DRUG

LBL-019 Injection

initial dose-MTD

DRUG

anti-PD-1 antibody injection

provide medicine base on needs

Trial Locations (6)

200433

RECRUITING

Shanghai Pulmonary Hospital, Shanghai

210000

RECRUITING

The first affiliated hospital with Nanjing medical university, Nanjing

350000

RECRUITING

Fujian Cancer Hospital, Fuzhou

410006

RECRUITING

Hunan Cancer Hospital, Changsha

430022

RECRUITING

Union hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan

430079

RECRUITING

Hubei Cancer Hospital, Wuhan

All Listed Sponsors
lead

Nanjing Leads Biolabs Co.,Ltd

INDUSTRY